A new study shows that 10 years of hormone therapy reduces the risk of breast-cancer recurrence. (Rui Vieira/Press Association via AP Images)CHICAGO -- Extending hormone therapy to 10 years significantly reduces the risk of a recurrence of breast cancer in many older women who have early-stage disease, according to a new study. He said the new research "provides direction for many patients and their doctors, confirming that prolonging aromatase inhibitor therapy can further reduce the risk of breast cancer recurrences." Those women benefited from taking the drug letrozole, part of a class of hormone therapies called aromatase inhibitors, for 10 years. While many women with early-stage breast cancer live for a long time, they “face an indefinite risk of relapse,” said lead study author, Paul Goss, director of breast cancer research at Massachusetts General Hospital.

Source: Washington Post June 05, 2016 11:26 UTC